This could be explained by the activation of both mechanisms—T-cell activation by atezolizumab and interferon, and the γ-mediated induction of PD-L1 expression through the reprograming of the tumor microenvironment into the active immune system by the VEGFR inhibitor [13]. The gene discussed is CD274; the disease is neoplasm.